Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: pramipexole

Registration Number: NCT00321854

Lead Sponsor: Boehringer Ingelheim

Brief Summary: This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 535

Inclusion Criteria

Ability to provide written informed consent in accordance with Good Clinical Practice (GCP) and local legislation;
Male or female patient with idiopathic Parkinson Disease (PD) confirmed by at least three of the following signs: resting tremor, bradykinesia, rigidity, and asymmetry (must have bradykinesia);
Parkinsons disease newly diagnosed within the past 2 years;
Patients with idiopathic PD characterized as Stage I-II by the Modified Hoehn and Yahr Scale who do not require PD medication and will not likely need PD medication for at least 6 months in the opinion of the investigator; Age 30 to 75 years at screening (Visit 1);
Women of childbearing potential must have a negative serum Beta-HumanChorionGonadotropin (Beta-HCG) pregnancy test at the Screening (Baseline) visit unless surgically sterile or post-menopausal (last menstruation 12 months prior to signing Informed Consent). Women of childbearing potential must be using a medically accepted contraceptive method. Acceptable methods of birth control are limited to: Intra-Uterine Device (IUD), oral, implantable, or injectable contraceptives, estrogen patch, and double barrier method (spermicide + diaphragm); and Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria

Previous history of allergic response or complications with pramipexole (PPX) or its excipients;
Atypical PD syndromes due to either drugs (e.g., metoclopramide, flunarizine) or metabolic disorders (e.g., Wilsons Disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy);
The patient is currently on L-dopa, dopamine agonists or other PD medication at baseline;
The patient has been on L-dopa, dopamine agonists or other PD medications for greater than 14 consecutive days prior to baseline;
If on L-dopa, dopamine agonists or other PD medications prior to baseline, the patient stopped treatment less than 30 days prior to baseline;
The patient has clinically significant abnormal laboratory values, and/or medical or psychiatric illness other than as seen in Parkinsons disease;
The patient has a clinically significant deviation from normal in the physical examination other than as seen in Parkinsons disease;
The patient has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery);
History of stereotactic brain surgery;
Surgery within 6 months of randomization, which in the opinion of the investigator, would negatively impact the patients participation in the study;
History of active epilepsy (i.e., occurrence of a seizure) within the past year;
Symptomatic orthostatic hypotension prior to randomization;
Malignant melanoma or history of previously treated malignant melanoma;
Patients who have received any of the following drugs (all time periods are calculated from randomization): Amantadine;
Electroconvulsive therapy during 180 days preceding the screening visit (Visit 1);
Patients who are currently pregnant or planning pregnancy during the study, or lactating;
Participation in other investigational drug studies or use of other investigational drugs within the previous 30 days prior to randomization;
History of psychosis;
A diagnosis of dementia

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Early Pramipexole	pramipexole	Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
Delayed Pramipexole	pramipexole	Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).

Primary Outcome Measures

Name	Time	Method
Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15	Baseline and Month 15	The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 15	Baseline and Month 15	The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 9	Baseline and Month 9	The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 6	Baseline and Month 6	The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Total Score at Month 3	Baseline and Month 3	The UPDRS total score (Parts I+II+III) measures the impact of PD on mentation, behaviour and mood, activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 176 (worst disability)
Change From Baseline in the Blinded Rater UPDRS Parts II+III Total Score at Month 15	Baseline and Month 15	The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 15	Baseline and Month 15	The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 9	Baseline and Month 9	The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 6	Baseline and Month 6	The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Parts II+III Score at Month 3	Baseline and Month 3	The UPDRS Parts II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (no disability) to 160 (worst disability)
Change From Baseline in the Blinded Rater UPDRS Part III Total Score at Month 15	Baseline and Month 15	The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 15	Baseline and Month 15	The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 9	Baseline and Month 9	The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 6	Baseline and Month 6	The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part III Score at Month 3	Baseline and Month 3	The UPDRS Part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (no disability) to 108 (worst disability)
Change From Baseline in the Blinded Rater UPDRS Part II Total Score at Month 15	Baseline and Month 15	The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 15	Baseline and Month 15	The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 9	Baseline and Month 9	The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 6	Baseline and Month 6	The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part II Score at Month 3	Baseline and Month 3	The UPDRS Part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (no disability) to 52 (worst disability)
Change From Baseline in the Blinded Rater UPDRS Part I Total Score at Month 15	Baseline and Month 15	The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 15	Baseline and Month 15	The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 9	Baseline and Month 9	The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 6	Baseline and Month 6	The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 3	Baseline and Month 3	The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Change From Baseline in the Investigator Rated UPDRS Part I Total Score at Month 3	Baseline and Month 3	The UPDRS Part I total score measures the impact of PD on mentation, behaviour and mood on an ordinal scale ranging from 0 (no disability) to 16 (worst disability)
Number of Responders Using the Blinded Rater Assessment of Clinical Global Impressions of Global Improvement (CGI-I) Score at Month 15	Month 15	The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse). Responders are defined as those patients with a CGI-I of 1 or 2.
Change From Baseline in Blinded Rater Assessment of Clinical Global Impressions of Severity of Illness (CGI-S) Category at Month 15	Baseline and Month 15	The CGI-S measures the participants severity of illness on an ordinal scale ranging from 1 (normal) to 7 (extremely ill). At Month 15 participants were categorised to 'Improved' (\>1 category improvement), 'Unchanged' or 'Worsened' (\>1 category worsening).
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 15	Baseline and Month 15	The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 9	Baseline and Month 9	The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Month 6	Baseline and Month 6	The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 15	Baseline and Month 15	The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Month 9	Baseline and Month 9	The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 15	Baseline and Month 15	The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Month 9	Baseline and Month 9	The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 15	Baseline and Month 15	The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)
Change From Baseline in the European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Score at Month 9	Baseline and Month 9	The EQ-VAS is a self rating of current health-related quality of life measured on a continuous scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state)
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 1	Month 1	The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 6	Month 6	The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 9	Month 9	The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 12	Month 12	The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Modified Minnesota Disorders Interview (MMIDI) Risk of Gambling at Month 15	Month 15	The MMIDI is a semi-structured interview designed to assess impulse control disorders; risk of gambling is assessed via 12 questions, a participant is considered at risk if answering 'Yes' to Q1 and 'Yes' to 5 or more of Q2 to Q12.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 1	Month 1	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 6	Month 6	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 9	Month 9	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 12	Month 12	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Sexual Behaviour at Month 15	Month 15	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive sexual behaviour is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1 and 'Yes' to 1 or more of Q2 to Q4.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 1	Month 1	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 6	Month 6	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 9	Month 9	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 12	Month 12	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Modified Minnesota Disorders Interview (MMIDI) for Compulsive Buying at Month 15	Month 15	The MMIDI is a semi-structured interview designed to assess impulse control disorders; compulsive buying is assessed via 4 questions, a participant is considered as being compulsive if answering 'Yes' to Q1a and 'Yes' to 1 or more of Q2a, Q3a and Q4a.
Percentage Change From Baseline in the Striatum Uptake at Month 15	Baseline and Month 15	The striatum beta-carbomethoxy-iodophenyl-tropane (beta-CIT) uptake was calculated as mean of the left and right caudate and putamen regions; measured by the Single-Photon Emission Computed Tomography (SPECT).
Clinically Significant Abnormalities in Clinical Laboratory Measurements - Haematology and Electrolytes	Baseline and Month 15
Clinically Significant Abnormalities in Clinical Laboratory Measurements - Enzymes	Baseline and Month 15
Clinically Significant Abnormalities in Clinical Laboratory Measurements - Substrates	Baseline and Month 15
Clinically Significant Abnormalities in Vital Signs	Baseline and Month 15

Trial Locations

Locations (99): 248.595.0102 Boehringer Ingelheim Investigational Site
🇺🇸
Traverse City, Michigan, United States
248.595.0103 Boehringer Ingelheim Investigational Site
🇺🇸
Atlanta, Georgia, United States
248.595.39012 Azienda Ospedaliera Pisana- Università degli Studi di Pisa
🇮🇹
Pisa, Italy
248.595.39006 Policlinico Universitario Molinette
🇮🇹
Torino, Italy
248.595.39007 Ospedale Evangelico Valdese
🇮🇹
Torino, Italy
248.595.0113 Boehringer Ingelheim Investigational Site
🇺🇸
Bradenton, Florida, United States
248.595.0140 Boehringer Ingelheim Investigational Site
🇺🇸
La Jolla, California, United States
248.595.0124 Boehringer Ingelheim Investigational Site
🇺🇸
Palm Beach Gardens, Florida, United States
248.595.3306C Centre Hospitalier du Pays d'Aix
🇫🇷
Aix en Provence, France
248.595.3301A Hôpital Gabriel Montpied
🇫🇷
Clermont Ferrand, France
248.595.3301B Hôpital Gabriel Montpied
🇫🇷
Clermont Ferrand, France
248.595.0122 Boehringer Ingelheim Investigational Site
🇺🇸
Brimingham, Alabama, United States
248.595.0109 Boehringer Ingelheim Investigational Site
🇺🇸
South Miami, Florida, United States
248.595.0115 Boehringer Ingelheim Investigational Site
🇺🇸
St. Petersburg, Florida, United States
248.595.0127 Boehringer Ingelheim Investigational Site
🇺🇸
Augusta, Georgia, United States
248.595.0134 Boehringer Ingelheim Investigational Site
🇺🇸
Baltimore, Maryland, United States
248.595.0141 Boehringer Ingelheim Investigational Site
🇺🇸
Worcester, Massachusetts, United States
248.595.43001 Boehringer Ingelheim Investigational Site
🇦🇹
Innsbruck, Austria
248.595.0107 Boehringer Ingelheim Investigational Site
🇺🇸
Dayton, Ohio, United States
248.595.49009 Boehringer Ingelheim Investigational Site
🇩🇪
Göttingen, Germany
248.595.0118 Boehringer Ingelheim Investigational Site
🇺🇸
Tulsa, Oklahoma, United States
248.595.3306B Centre Hospitalier du Pays d'Aix
🇫🇷
Aix en Provence, France
248.595.49005 Boehringer Ingelheim Investigational Site
🇩🇪
Hannover, Germany
248.595.3307B Hôpital Roger Salengro
🇫🇷
Lille cedex, France
248.595.3302A Hôpital La Timone
🇫🇷
Marseille cedex 05, France
248.595.43005 Boehringer Ingelheim Investigational Site
🇦🇹
Bruck a. d. Mur, Austria
248.595.43003 Boehringer Ingelheim Investigational Site
🇦🇹
Graz, Austria
248.595.0114 Boehringer Ingelheim Investigational Site
🇺🇸
Warwick, Rhode Island, United States
248.595.0129 Boehringer Ingelheim Investigational Site
🇺🇸
New York, New York, United States
248.595.0136 Boehringer Ingelheim Investigational Site
🇺🇸
Winston Salem, North Carolina, United States
248.595.0120 Boehringer Ingelheim Investigational Site
🇺🇸
Cleveland, Ohio, United States
248.595.3305A Hôpital Purpan
🇫🇷
Toulouse cedex 9, France
248.595.35801 Boehringer Ingelheim Investigational Site
🇫🇮
Oulu, Finland
248.595.43002 Boehringer Ingelheim Investigational Site
🇦🇹
Wien, Austria
248.595.35804 Boehringer Ingelheim Investigational Site
🇫🇮
Lahti, Finland
248.595.3307A Hôpital Roger Salengro
🇫🇷
Lille cedex, France
248.595.3303A Cabinet Médical
🇫🇷
Evreux, France
248.595.3305C Hôpital Purpan
🇫🇷
Toulouse cedex 9, France
248.595.49016 Boehringer Ingelheim Investigational Site
🇩🇪
Gera, Germany
248.595.49006 Boehringer Ingelheim Investigational Site
🇩🇪
Augsburg, Germany
248.595.49004 Boehringer Ingelheim Investigational Site
🇩🇪
Hamburg, Germany
248.595.39001 Azienda Ospedaliera Istituti Clinici di Perfezionamento
🇮🇹
Milano, Italy
248.595.39004 Università degli Studi di Bari
🇮🇹
Bari, Italy
248.595.49015 Boehringer Ingelheim Investigational Site
🇩🇪
München, Germany
248.595.39009 Ospedale di Bellaria
🇮🇹
Bologna, Italy
248.595.39005 Ospedale della Misericordia
🇮🇹
Grosseto, Italy
248.595.39010 Ospedale Maggiore Policlinico Mangigalli e Regina Elena
🇮🇹
Milano, Italy
248.595.39011 Ospedale S. Raffaele - IRCCS
🇮🇹
Milano, Italy
248.595.39002 Università Federico II
🇮🇹
Napoli, Italy
248.595.39003 Ospedale di Viareggio
🇮🇹
Viareggio, Italy
248.595.34003 Hospital de Alcorcon
🇪🇸
Alcorcon (Madrid), Spain
248.595.81001 Juntendo University Hospital
🇯🇵
Bunkyo-ku, Tokyo, Japan
248.595.81002 Kagawa Prefectural Central Hospital
🇯🇵
Takamatsu, Kagawa, Japan
248.595.46004 Boehringer Ingelheim Investigational Site
🇸🇪
Jönköping, Sweden
248.595.46006 Boehringer Ingelheim Investigational Site
🇸🇪
Linköping, Sweden
248.595.34001 Hospital Clinic i Provincial of Barcelona
🇪🇸
Barcelona, Spain
248.595.34002 Nuevo Hospital de Sant Pau
🇪🇸
Barcelona, Spain
248.595.34005 Hospital Mutua de Terrassa
🇪🇸
Tarrasa (Barcelona), Spain
248.595.34004 Hospital 12 de Octubre
🇪🇸
Madrid, Spain
248.595.46005 Boehringer Ingelheim Investigational Site
🇸🇪
Norrköping, Sweden
248.595.44005 Boehringer Ingelheim Investigational Site
🇬🇧
Stoke-on-Trent, United Kingdom
248.595.44003 Boehringer Ingelheim Investigational Site
🇬🇧
Birmingham, United Kingdom
248.595.44002 Boehringer Ingelheim Investigational Site
🇬🇧
Newark, United Kingdom
248.595.44008 Boehringer Ingelheim Investigational Site
🇬🇧
Glasgow, United Kingdom
248.595.44001 Boehringer Ingelheim Investigational Site
🇬🇧
Newcastle upon Tyne, United Kingdom
248.595.44010 Boehringer Ingelheim Investigational Site
🇬🇧
North Shields, United Kingdom
248.595.44011 Boehringer Ingelheim Investigational Site
🇬🇧
Romford, United Kingdom
248.595.44004 Boehringer Ingelheim Investigational Site
🇬🇧
London, United Kingdom
248.595.0133 Boehringer Ingelheim Investigational Site
🇺🇸
La Jolla, California, United States
248.595.0101 Boehringer Ingelheim Investigational Site
🇺🇸
Chicago, Illinois, United States
248.595.0131 Boehringer Ingelheim Investigational Site
🇺🇸
Scarbourough, Maine, United States
248.595.0123 Boehringer Ingelheim Investigational Site
🇺🇸
Panama City, Florida, United States
248.595.0105 Boehringer Ingelheim Investigational Site
🇺🇸
Gainesville, Florida, United States
248.595.0119 Boehringer Ingelheim Investigational Site
🇺🇸
Hollywood, Florida, United States
248.595.0121 Boehringer Ingelheim Investigational Site
🇺🇸
Kirkland, Washington, United States
248.595.0139 Boehringer Ingelheim Investigational Site
🇺🇸
Raleigh, North Carolina, United States
248.595.3306A Centre Hospitalier du Pays d'Aix
🇫🇷
Aix en Provence, France
248.595.3302B Hôpital La Timone
🇫🇷
Marseille cedex 05, France
248.595.49008 Boehringer Ingelheim Investigational Site
🇩🇪
Berlin, Germany
248.595.49011 Boehringer Ingelheim Investigational Site
🇩🇪
Bonn, Germany
248.595.49010 Boehringer Ingelheim Investigational Site
🇩🇪
Hanau, Germany
248.595.49007 Boehringer Ingelheim Investigational Site
🇩🇪
Bochum, Germany
248.595.49012 Boehringer Ingelheim Investigational Site
🇩🇪
Leipzig, Germany
248.595.49001 Boehringer Ingelheim Investigational Site
🇩🇪
Marburg, Germany
248.595.49014 Boehringer Ingelheim Investigational Site
🇩🇪
Tübingen, Germany
248.595.39013 Ospedale Umberto I
🇮🇹
Venezia Mestre, Italy
248.595.39014 Boehringer Ingelheim Investigational Site
🇮🇹
Roma, Italy
248.595.46001 Boehringer Ingelheim Investigational Site
🇸🇪
Stockholm, Sweden
248.595.46002 Boehringer Ingelheim Investigational Site
🇸🇪
Örebro, Sweden
248.595.46007 Boehringer Ingelheim Investigational Site
🇸🇪
Stockholm, Sweden
248.595.0137 Boehringer Ingelheim Investigational Site
🇺🇸
Columbus, Georgia, United States
248.595.0111 Boehringer Ingelheim Investigational Site
🇺🇸
Elk Grove Village, Illinois, United States
248.595.0112 Boehringer Ingelheim Investigational Site
🇺🇸
New Haven, Connecticut, United States
248.595.0106 Boehringer Ingelheim Investigational Site
🇺🇸
Tampa, Florida, United States
248.595.0108 Boehringer Ingelheim Investigational Site
🇺🇸
Houston, Texas, United States
248.595.0104 Boehringer Ingelheim Investigational Site
🇺🇸
Scottsdale, Arizona, United States
248.595.43004 Boehringer Ingelheim Investigational Site
🇦🇹
Wien, Austria
248.595.35803 Boehringer Ingelheim Investigational Site
🇫🇮
Helsinki, Finland
248.595.0116 Boehringer Ingelheim Investigational Site
🇺🇸
Memphis, Tennessee, United States